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1. Introduction 
 
Sepsis causes an estimated 240,000 deaths per year in the United States [1] and 
around 3000 deaths/year in Switzerland [2]. Despite enormous efforts to develop new 
drugs for treating sepsis, only one single compound has come to market so far, the 
recombinant human clotting factor activated protein C (APC) [3]. APC was found to be 
beneficial for patients with severe sepsis, however it has dose limiting side effects such 
as bleeding complications [4]. Therefore, it is crucial to understand the mode of action of 
APC in septic patients to come up with novel and better treatment strategies [5-7].   
Almost a decade ago I became involved in studying how APC mediates protective 
effects. At that time it was generally assumed that anticoagulatory effects of APC might 
mediate benefits through prevention from microthrombosis [8, 9]. Nevertheless 
alternative non anticoagulant mechanisms of APC were proposed [10]: In vitro, APC 
was shown to cleave and activate the thrombin receptor, the protease activated 
receptor 1 (PAR1) in an EPCR dependent manner [11]. However the physiological 
relevance of this novel signaling pathway was controversially discussed. Arguments 
included the fact that the generation of APC requires the presence of thrombin in the 
first place [9]. It was argued that thrombin would have already activated all available 
PAR1 at the time when APC would become available [9].  
In my studies my colleagues and I assumed that protease binding to co-receptors might 
affect the relative efficiency of thrombin and APC in cleaving PAR1 and we could show 
that in fact, APC was able to cleave and activate PAR1 and subsequently mediate 
endothelial barrier sealing effects despite the presence of thrombin [12]. Beyond 
cleavage of PAR1, APC-PAR1 could also be shown to mediate physiologically relevant 
effects in endothelial cells in the presence of thrombin. Thus we were able to give 
evidence, that the APC-PAR1 pathway was indeed a physiologically relevant clotting 
protease signaling pathway. Subsequent studies confirmed our findings [13]. Mice 
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studies further identified PAR1 as the target receptor for the high dose APC treatment 
which mediates many beneficial effects in the mouse injury model [6].  
Next our group addressed the question if the high dose APC treatment in the mouse 
injury model reflects the situation of prolonged infusions of low dose APC which is used 
in humans suffering from severe sepsis. In humans APC treatment is achieved with 
APC plasma concentrations up to 100 times lower that the ones used in mice. Further 
the highly related receptors PAR3 and 4 show substantial functional differences 
between mouse and man [14]. We asked whether APC cleaves and activates PAR1 
similarly in mouse and man and whether prolonged infusions of low dose APC still 
mediate PAR1 dependent beneficial effects in a mouse injury model [15]. Our studies 
could not relieve species differences, further corroborating that also in humans the 
APC-PAR1 signaling pathway mediates benefits in systemic inflammation such as 
sepsis.  
While screening for ways to eventually dissect anticoagulant form signaling proprieties 
of APC we studied secondary side interactions between APC and substrates [16]. 
Further we looked at the binding interaction of APC’s Gla domain to the endothelial 
protein C (co-) receptor (EPCR). Unexpectedly, we found that in addition to APC the 
structurally related clotting factor X and its activated form (FXa) also firmly bind EPCR 
[17]. Although it remains unclear whether the interaction of FXa and EPCR is of direct 
physiological importance, it might well explain some clinical observations. Only in 
patients with a severely altered clotting system (i.e. depleted clotting factors) 
therapeutically infused APC is efficient [18]. Given the very low concentrations of 
therapeutically infused APC (0.5nM) competition by FX (200nM) for EPCR binding 
might well explain the inefficiency of APC in patients with unaltered clotting system.  
To summarize, these studies help to better understand the target mechanism of 
therapeutically infused APC in systemic inflammation in humans and have helped to 
design future mutants of APC which are currently under investigation in my laboratory 
and which will hopefully help to improve therapeutic effects of APC. 
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2. Results 
2.1. Activated protein C-cleaved protease activated receptor-1 is retained on the 
endothelial cell surface even in the presence of thrombin.  
Blood. 2008 Mar 1;111(5):2667-73 [12] 
A corner stone of inflammatory diseases such as sepsis is the increased vascular 
permeability resulting in hypovolemic shock and upon intravenous volume therapy in 
interstitial edema [19]. Here we used our established in vitro model quantifying the 
endothelial barrier function [20]. EA.hy.926 endothelial cells were grown on a 
microporose membrane separating two compartments. Into the apical compartment 
which represents the intravascular room, Evans Blue labelled albumin was placed. To 
quantify the endothelial barrier function, the amount of dye passing through the 
endothelial layer was quantified in the bottom (interstitial) compartment. With this 
system we could show that APC can induce powerful barrier protective responses. 
Whereas endothelial barrier enhancing effects of APC have previously been shown to 
depend on binding of APC to the endothelial protein C (co-) receptor and cleavage of 
PAR1, it was controversially discussed if APC generated by thrombin still can act 
through PAR1 [8, 9]. In experiments where APC and thrombin were added together 
onto endothelial cells, we could show that APC still mediates barrier enhancing effects. 
And even when thrombin was added together with the non proteolytically active 
xymogen protein C the over time generated APC was still efficient in inducing barrier 
sealing effects, rising questions about the underlying mechanism. 
Using cell surface immunoassays with conformation sensitive monoclonal anti-PAR1 
antibodies we quantified cleavage and trafficking of endogenous expressed PAR1 on 
the endothelial cell surface following incubation with APC in the absence and presence 
of thrombin. Incubation with APC caused efficient PAR1 cleavage and upon co-
incubation with thrombin APC still supported additional PAR1 cleavage. Thrombin-
cleaved PAR1 rapidly disappeared from the cell surface whereas, unexpectedly, the 
APC-cleaved PAR1 remained and could be detected on the cell surface, even when 
thrombin at concentrations of up to 1 nM was also present.  
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These findings demonstrated for the first time directly that APC can mediate biological 
effects under physiological conditions where thrombin is also present. Further, they 
provide a molecular model on how APC acts on PAR1 by suggesting a distinct PAR1 
population on endothelial cells with specific trafficking proprieties witch seems 
susceptible to APC but not to thrombin.  
 
2.2. Protection of Vascular Barrier Integrity by Activated Protein C Dependent 
on Protease-Activated Receptor-1  
Thromb Haemost. 2009 Apr;101(4):724-33 [15] 
The mode of action of therapeutically infused APC in patients with sepsis is 
controversially discussed [21]. Mouse models are of key importance to clarify target 
mechanisms of drugs in translational research but species differences may limit 
conclusions. We analyzed whether mouse APC can cleave, activate and induce 
signaling through murine PAR1. In newly established mouse models we tested if long 
term infusion with low does APC, as it is used in humans, prevents from vascular 
leakage in a mouse model and if beneficial effects can be explained by APC signaling 
through the PAR1 pathway in mice. Cell surface immunoassays demonstrated efficient 
cleavage of endogenous murine endothelial PAR1 by either murine or human APC. Of 
importance, there were no species differences detected in how APC cleaves PAR1 and 
in regard to the specific receptor kinetics of APC-cleaved PAR1. Pharmacological 
concentrations of APC of either species had powerful barrier protective effects on 
cultured murine endothelial cells and required PAR1 cleavage. In vivo, vascular 
endothelial growth factor-mediated hyperpermeability in the skin of wild type mice was 
reduced by either endogenously generated or by directly infused recombinant mouse 
APC. Similarly long term infusions of low dose APC, as used in humans with sepsis [3], 
reduced lung edema formation in mice suffering from systemic inflammation induced by 
endotoxin in a PAR1 dependent manner.  
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Our results directly show that murine APC cleaves and signals through PAR1 in murine 
endothelial cells. Further we could not find any evidence for species differences 
between mouse and man in terms of how APC cleaves and activates PAR1. Prolonged 
infusions of low dose APC reduce the vascular permeability in mouse models and PAR1 
plays a major role in mediating these effects.  
Together these in vitro and in vivo data support the paradigm that PAR1 contributes to 
protective effects of APC on vascular barrier integrity in sepsis. 
 
2.3. Clotting Factor Xa Cleaves PAR1 and Mediates Signaling Dependent on 
Binding to the Endothelial Protein C Receptor  
J Thromb Haemost. 2010 Feb;8(2):379-88 [17] 
Coagulation is intrinsically tied to inflammation, and both pro-inflammatory and anti-
inflammatory responses are modulated by coagulation protease signaling through 
protease-activated receptor-1 (PAR1). Activated factor X (FXa) can elicit cellular 
signaling through PAR1 [22], but little is known about the role of cofactors in this 
pathway. 
Endothelial protein C receptor (EPCR) supports PAR1 signaling by APC. So far it 
remains unclear if other Gla-domain containing proteases such as FXa compete with 
APC for EPCR binding and subsequent activation of PAR1. We were especially 
interested if FX can compete with APC for EPCR, given the high physiological plasma 
concentration of FXa of around 200nM.  
We tested if FXa binds to EPCR in endothelial cells which i) either natively expressed 
EPCR or ii) in endothelial cells in which EPCR expression was down regulated or in 
CHO-K1 cells which iii) either did not or iv) stably overexpress EPCR. We found that 
FXa binds to both natively and overexpressed EPCR with proprieties comparable to 
protein C or APC. Further we found that FXa competes for EPCR binding with protein 
8 
 
C, APC and clotting factor VII but not with protein S which also shares a high homology 
to all EPCR binding clotting proteases and also contains a Gla-domain.  
PAR1 cleavage by FXa as analyzed with conformation-sensitive antibodies and a 
tagged PAR1 reporter construct was strongly enhanced if EPCR was available. Anti-
EPCR failed to affect the tissue factor-dependent activation of FX, but high 
concentrations of FXa decreased EPCR-dependent protein C activation. Most 
importantly, the FXa-mediated induction of Erk1/2 activation, expression of the 
transcript for connective tissue growth factor and barrier protection in endothelial cells 
required binding to EPCR.  
Taken together, these results demonstrate that EPCR plays an unexpected role in 
supporting cell surface recruitment, PAR1 activation, and signaling by FXa. Further the 
similar binding proprieties of FXa and protein C or APC together with evidence for direct 
competition for EPCR binding provide a model for why therapeutic infusions of low dose 
APC were efficient only in patients with severely depleted clotting factor concentrations. 
In patients having unaffected clotting factor concentrations, the physiological 
concentration of FX (200nM) might well compete with the therapeutic concentration of 
APC (0.5nM) for their target co-receptor EPCR.   
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HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
Activated protein C–cleaved protease activated receptor-1 is retained on the
endothelial cell surface even in the presence of thrombin
Reto A. Schuepbach,1 Clemens Feistritzer,1 Lawrence F. Brass,2 and Matthias Riewald1
1Department of Immunology, Scripps Research Institute, La Jolla, CA; and 2University of Pennsylvania, Philadelphia
Activated protein C (APC) signals in endo-
thelial cells ex vivo through protease acti-
vated receptor-1 (PAR1). However, it is
controversial whether PAR1 can mediate
APC’s protective effects in sepsis be-
cause the inflammatory response results
in thrombin generation and thrombin pro-
teolytically activates PAR1 much more
efficiently than APC. Here we show that
APC can induce powerful barrier protec-
tive responses in an endothelial cell
monolayer in the presence of thrombin.
Using cell surface immunoassays with
conformation sensitive monoclonal anti-
PAR1 antibodies we analyzed cleavage of
endogenous PAR1 on the endothelial cell
surface by APC in the absence and pres-
ence of thrombin. Incubation with APC
caused efficient PAR1 cleavage and upon
coincubation with thrombin APC sup-
ported additional PAR1 cleavage.
Thrombin-cleaved PAR1 rapidly disap-
peared from the cell surface whereas,
unexpectedly, the APC-cleaved PAR1 re-
mained and could be detected on the cell
surface, even when thrombin at concen-
trations of up to 1 nM was also present.
Our findings demonstrate for the first
time directly that APC can generate a
distinct PAR1 population on endothelial
cells in the presence of thrombin. The
data suggest that different trafficking of
activated PAR1 might explain how PAR1
signaling by APC can be relevant when
thrombin is present. (Blood. 2008;111:
2667-2673)
© 2008 by The American Society of Hematology
Introduction
Recombinant human activated protein C (APC) has powerful
protective effects in systemic inflammation that led to its approval
to treat patients with severe sepsis.1 Protein C (PC) is physiologi-
cally activated on the endothelial cell surface by the key procoagu-
lant enzyme thrombin and APC down-regulates thrombin forma-
tion in a negative feedback loop.2 However, this anticoagulant
effect of APC is unlikely to explain its benefit in systemic
inflammation because other anticoagulants with comparable effect
do not improve survival in septic patients3,4 or in animal models.5
More recently, APC signaling through protease activated
receptor-1 (PAR1) emerged as an alternative mechanism for APC’s
beneficial effects.6,7 In cultured endothelial cells PAR1 mediates
protective effects of APC on gene expression,6,8 survival,9,10 and
barrier integrity.11 PAR1 has also been implicated in mouse models
analyzing neuroprotective effects of APC in vivo.9,12,13 PAR1 is a
7-transmembrane G-protein–coupled receptor that is enzymatically
cleaved after Arg41 to expose a new extracellular N-terminus that
acts as a tethered activating ligand.14 PAR1 is the prototypical
thrombin receptor and thrombin cleaves and activates PAR1 with
high efficiency because it directly binds to PAR1 in an orientation
that favors cleavage.15 In contrast, APC needs to be recruited to a
coreceptor, the endothelial protein C receptor (EPCR), to induce
PAR1-dependent signaling6 but APC remains less efficient than
thrombin.16 Systemic inflammation leads to generation of thrombin
and in view of the relatively low efficiency of PAR1 activation by
APC it has been argued that a role of APC-PAR1 signaling in
sepsis is unlikely.16,17
Here we demonstrate that APC can mediate significant PAR1
cleavage even in the presence of thrombin. In contrast to thrombin-
cleaved PAR1, the APC-cleaved PAR1 accumulates on the endothe-
lial cell surface. The findings support the concept that PAR1 can
mediate protective APC signaling in conditions where thrombin is
also present.
Methods
Reagents and assays
Human thrombin was as described.6,18 Human plasma–derived APC and PC
were from Haematologic Technologies (Essex Junction, VT). Recombinant
human wild-type APC and mutant APC S360A were a gift from Dr John
Griffin (Scripps Research Institute, La Jolla, CA).19 All experiments
involving stimulation with APC included hirudin (Calbiochem, La Jolla,
CA) unless indicated otherwise or if cells were coincubated with APC and
thrombin. Control experiments demonstrated that hirudin alone had no
effect in any of our assays. Brefeldin A was from Calbiochem. Monoclonal
anti-PAR1 ATAP2, WEDE15, and SPAN11 were as described.20,21 Monoclo-
nal rat anti-EPCR RCR-92 (nonblocking) and RCR-252 (blocking) were
provided by Dr Kenji Fukudome (Saga Medical School, Saga, Japan) and
were used at 25 g/mL.22 Amidolytic assays for APC activity were as
described previously.23
Cell culture, permeability assay, and surface immunoassays
EA.hy926 cells24 and primary human umbilical vein endothelial cells
(HUVEC; Cascade Biologics, Portland, OR) were cultivated and macromo-
lecular monolayer permeability was analyzed in a dual chamber system
using Evans blue-labeled bovine serum albumin (BSA) as described
previously.11 For cell-surface enzyme linked immunoassays (ELISA), the
cells were fixed with 2% paraformaldehyde, blocked with 1% BSA and
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probed with anti-PAR1 antibodies at 0.5 g/mL for 30 minutes. A
horseradish peroxidase (HRP)–coupled goat anti-mouse antibody and
tetrametylbenzidine were used for spectrophotometric quantification of
anti-PAR1 binding. To facilitate the comparison of different experiments
the quantification of antibody binding was normalized. Specific blocking
peptides TFLLRNPNDK (for ATAP2), KYEPFWEDEEKNES (for
WEDE15), and NATLDPRSFFLR (for SPAN11) were custom made
(Invitrogen, Carlsbad, CA) and all peptides completely blocked the
respective specific anti-PAR1 staining. Residual unspecific staining was
found to be unaffected by agonists and was subtracted to correct for
background (0% staining). In all experiments nonagonist-treated cells were
included and PAR1 staining in these cells was defined as 100%. The shown
data were generated using EA.hy926 cells and results were confirmed in
HUVECs. For immunofluorescence microscopy EA.hy926 cells were
grown, fixed, and stained on glass cover slides using identical conditions as
for ELISA. Alexa Fluor 488-coupled goat antimouse (Invitrogen) was used
as the secondary antibody. The cover slides were extensively washed,
mounted (Gelmount; Sigma-Aldrich, St Louis, MO), and immediately
analyzed using an Olympus BX60 fluorescence microscope (Olympus,
San Diego, CA).
Biotinylation of cell-surface proteins and Western blotting
After agonist incubation, proteases were quenched, EA.hy926 cells were
washed twice on ice and kept at 4°C for all subsequent steps. Cell-surface
proteins were biotinylated (0.2 mg/mL Sulfo-NHS-SS-biotin for 30 min-
utes; Pierce, Rockford, IL) before extraction in RIPA buffer supplemented
with Complete Protease Inhibitor Cocktail (Roche, Indianapolis, IN),
20 M bestatin, and 0.1 mg/mL phenylmethylsulfonyl fluoride. Biotinyl-
ated proteins were collected using streptavidin agarose (Invitrogen).
Proteins were analyzed by sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) under reducing conditions, transferred to
Immobilon-P-membranes (Millipore, Bedford, MA), blocked with dry
milk, and probed with WEDE15 or ATAP2 followed by HRP-coupled goat
antimouse and visualization using the Femto detection system (Pierce). In
blots showing non–cell-surface proteins loading was assessed using anti–-
actin (Sigma-Aldrich) followed by HRP-coupled goat antirabbit. Optical
density of immunoreactive bands was assessed using Scion Image Alpha
4.0.3.2 software (Frederick, MD).
Statistical analysis
Data analysis was performed using the NCSS Statistical & Power Analysis
or SigmaStat 3.5 (Systat Software, San Jose, CA) software. A 2-sample
2-tailed homoscedastic t test was used to calculate the indicated P values.
Results
APC can induce endothelial barrier protective signaling in the
presence of thrombin
Enhancement of endothelial barrier integrity is a sensitive readout
for PAR1-dependent signaling by exogenous and endogenously
generated APC.11,23 To test if APC-PAR1 signaling still occurs
when thrombin is present at concentrations that are expected to lead
to rapid cleavage of the available PAR1, we determined whether
locally generated APC can still mediate protective effects in the
presence of 1 nM thrombin. Neither thrombin alone nor PC
zymogen affected permeability of a monolayer of endothelial cells
in a dual chamber system after 3 hours of incubation. However,
when the cells were coincubated with thrombin and PC, the
generated APC significantly enhanced the barrier function (Figure
1A). We next studied the effect of increasing thrombin concentra-
tions on APC’s barrier enhancing effects. To only vary the thrombin
but not the APC concentration, APC was exogenously added in
these experiments, although exogenous APC is less efficient than
endogenously generated APC. Again APC enhanced the barrier
integrity despite the presence of up to low-nanomolar thrombin
concentrations (Figure 1B). These data indicate that exogenous and
endogenously generated APC still mediate barrier protective ef-
fects even if thrombin is also present. The possibility that thrombin
becomes inhibited or sequestered, allowing APC to induce protec-
tive effects through newly externalized PAR1,25 was ruled out in
control experiments that demonstrated that thrombin’s proteolytic
activity in the cell medium was stable under our experimental
conditions (not shown).
Quantification of endogenous PAR1 on the endothelial cell
surface by immunoassays
Because it is not possible to directly prove that APC’s barrier
enhancing effects in the presence of thrombin-PAR1 signaling still
depend on PAR1 cleavage, we established assays to assess cleavage
of endogenous PAR1 by APC and thrombin alone and in combina-
tion. A tagged PAR1 construct has been used to measure PAR1
cleavage in a previous report.16 However, such transfected PAR1
constructs were later shown to have decreased susceptibility
toward cleavage by APC as compared with endogenously ex-
pressed PAR1, most likely because of relative unavailability of
EPCR.26 We therefore established a quantitative cell-surface ELISA
to analyze how cleavage and/or conformation of endogenous
endothelial cell PAR1 are affected. Control experiments using
Figure 2. Quantification of cell surface–exposed PAR1. Confluent EA.hy926 cells
were incubated for 3 hours with the indicated agonists. Apical expression of PAR1
was analyzed in a cell-surface ELISA using monoclonal anti-PAR1 antibodies
SPAN11, ATAP2, and WEDE15. Results are shown relative to control (means  SEM,
n  9, **P  .005).
Figure 1. Protective signaling by APC in the presence of thrombin. EA.hy926
cells in a dual-chamber system were incubated for 3 hours with the indicated agonists
in the top chamber followed by analysis of permeability. Means plus or minus SEM
with n  5 (A) and 10 (B). **P  .005.
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immunofluorescence microscopy demonstrated that the anti-PAR1
antibodies under conditions used for the ELISA indeed only bind to
cell surface PAR1 and do not detect intracellular pools (Figure
S1A, available on the Blood website; see the Supplemental
Materials link at the top of the online article). Thrombin dose–
dependently down-regulated binding of 3 monoclonal antibodies
that were raised against the N-terminal exodomain of human PAR1,
ie, SPAN11, ATAP2, and WEDE1520,21 (Figure 2), consistent with
the expected cleavage and internalization of PAR1.27 APC incuba-
tion strongly decreased binding of the cleavage-sensitive SPAN11,
indicating that APC reduces surface availability of native, un-
cleaved PAR1. Binding of the non–cleavage-sensitive WEDE15,
which binds to an epitope downstream from the Arg41 cleavage
site in PAR1’s N-terminal exodomain, was not affected by APC,
indicating that levels of total surface PAR1 remain constant. These
data demonstrate for the first time directly that incubation with
APC leads to cleavage of endogenous endothelial cell PAR1. APC
down-regulated ATAP2 binding although ATAP2 also binds to an
epitope downstream from the Arg41 cleavage site and is regarded
as a non–cleavage-sensitive anti-PAR1. This unexpected result
indicates that the APC-cleaved PAR1 is detected on the cell surface
by WEDE15 but not by ATAP2. ATAP2 recognizes PAR1’s
Leu44-Arg46 amino acid stretch while WEDE15 binds further
downstream at Phe55-Glu60.20,21 Previous data indicate that APC
can only directly cleave PAR1’s N-terminal exodomain at Arg41.28
Incubation with APC might lead to activation of other cellular
proteases that in turn might cleave PAR1 at additional sites and
cause shedding of the ATAP2 but not the WEDE15 epitope.
However, effects of APC on ATAP2 staining were found to be
comparable in native cells and cells that have been fixed before
agonist incubation (Figure 3A), suggesting that loss of ATAP2
binding is mediated by a conformational change after cleavage.
Western blotting of biotinylated cell-surface proteins was used to
test whether the ATAP2 epitope can be detected in denatured
cleaved PAR1 after APC incubation. The surface biotinylation–
based assay does not detect intracellular PAR1, as shown in control
experiments (Figure S1B). PAR1 migrated as an elongated immu-
noreactive band as reported earlier and prolonged incubation with
APC led to a cleavage product at the expected smaller size.28,29
Both WEDE15 and ATAP2 anti-PAR1 similarly detected native
and cleaved PAR1 (Figure 3B). The ATAP2 epitope in APC-
cleaved PAR1 is thus not shed or degraded and becomes available
for ATAP2 binding in denatured PAR1. In conclusion, WEDE15 is
a non–cleavage-sensitive antibody and detects total PAR1 in both
native (ELISA) and denaturing (Western blotting) conditions.
ATAP2 does also bind to cleaved and uncleaved denatured PAR1;
however, it is conformation sensitive and does not bind to the
cleaved PAR1 in the cell-surface immunoassay.
PAR1 cleavage by APC
Given that ATAP2 is commercially available and sensitive to the
conformational change upon cleavage of PAR1 we used this
antibody to assess cleavage of endogenously expressed PAR1.
Results were confirmed using SPAN11 as indicated below. APC
and thrombin down-regulated the binding of ATAP2 in a time
dependent manner and 20 nM of APC was similarly efficient as
40 pM thrombin (Figure 4A). A proteolytically inactive recombi-
nant APC variant with an S3A substitution at the active center did
not affect ATAP2 binding (Figure 4B). As expected, PAR1 cleavage
by APC was completely inhibited in the presence of an antibody
against EPCR that blocks APC binding to EPCR (Figure 4C). In
contrast, APC significantly down-regulated ATAP2 binding in the
presence of nonblocking anti-EPCR, albeit to a lesser extent than in
the absence of antibody. A possible explanation for the effect of
nonblocking anti-EPCR might be that the antibody leads to
clustering and internalization of EPCR during the 3-hour experi-
ment. Down-regulation of ATAP2 binding in response to APC thus
requires both APC’s proteolytic activity and APC binding to EPCR.
For all subsequent experiments analyzing effects of exogenously
added APC a concentration of 20 nM was used and agonist
Figure 3. ATAP2 does not detect PAR1’s active conformation generated after
scissile bond cleavage. (A) ATAP2 binding was quantified by cell-surface ELISA
after incubation for 3 hours with the indicated agonists in cells before and after fixation
with paraformaldehyde (PFA). PMA indicates phorbol myristate acetate (0.1 g/mL).
Means plus or minus SEM are shown (n  12). (B) Cells were incubated for 3 hours
with control or APC (20 nM) and biotinylated surface proteins were analyzed by
Western blotting with WEDE15 or ATAP2 as indicated. A representative experiment of
3 is shown.
Figure 4. APC down-regulates ATAP2 binding dependent on proteo-
lytic activity and EPCR binding. (A) ATAP2 binding was quantified by
ELISA after incubation with the indicated agonists in time course
experiments. (B) Cells were incubated for 3 hours with the indicated
concentrations of recombinant wild-type APC or proteolytically inactive
APC S360A and ATAP2 binding was quantified. (C) Cells were preincu-
bated (10 minutes) in the absence and presence of nonblocking
(RCR-92) or blocking (RCR-252) anti-EPCR (25 g/mL) followed by
3 hours of incubation with the indicated agonists and quantification of
ATAP2 binding. Means plus or minus SEM are shown (n  6 in panels
A,C; n  9 in panel B. **P  .005).
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incubation was for 3 hours to obtain significant EPCR-dependent
cleavage of PAR1.
APC can mediate additional PAR1 cleavage even if thrombin is
also present
When APC was coincubated with thrombin an additional loss of
ATAP2 binding was detected (Figure 5A). APC also caused an
additional loss of ATAP2 binding in cells that were fixed before
agonist incubation consistent with direct effects of APC on PAR1.
Endothelial cells have intracellular pools of PAR1 and previous
studies have shown that both native and cleaved PAR1 are
translocated to the cell surface upon agonist treatment.20,25 As
shown in Figure 5B, the cell surface was repopulated with PAR1
after a high-dose thrombin challenge with similar kinetics in the
EA.hy926 cell line as described previously for HUVECs. Brefeldin
A, an inhibitor of vesicle trafficking that blocks exocytosis but not
internalization of membrane proteins,30 prevented repopulation of
the cell surface with ATAP2 binding sites (Figure 5B). When
surface repopulation was blocked with brefeldin A, APC caused a
significant additional loss of ATAP2 binding in the presence of up
to 360 pM thrombin (Figure 5C). Similar results were obtained
using the cleavage-sensitive antibody SPAN11 (not shown). We
have previously shown that the endogenous PC activation pathway
is mechanistically linked to efficient PAR1-dependent protective
signaling.23 Consistent with these results, when cells were incu-
bated with thrombin in the presence of PC zymogen, ATAP2
binding (and SPAN11 binding; not shown) was further decreased
even when only low nM APC was generated (Figure 5D).
APC-cleaved PAR1 is inefficiently removed from the
cell surface
Given that EA.hy926 cells can rapidly externalize PAR1 to the cell
surface after agonist treatment (Figure 5B), our finding that APC
does not affect WEDE15 binding (Figure 2) could be explained by
efficient repopulation of the cell surface with cleaved and/or
uncleaved PAR1 from intracellular pools. However, APC did not
down-regulate WEDE15 staining even in the presence of brefeldin
A (Figure 6A), demonstrating that, in contrast to thrombin-cleaved
PAR1, APC-cleaved PAR1 is retained on the cell surface. The
cleaved PAR1 present on the cell surface after APC incubation was
still retained after a subsequent incubation with high-dose thrombin
(Figure 6B).
These results raise the possibility that APC-cleaved PAR1 might
accumulate on the cell surface even in the presence of thrombin.
When ATAP2 (detects only uncleaved PAR1) and WEDE15
(detects both cleaved and uncleaved PAR1) binding was analyzed
in parallel experiments after incubation with increasing concentra-
tions of thrombin alone, staining with both antibodies was almost
identical (Figure 7A). This finding indicates that no detectable
cleaved PAR1 is retained on the cell surface upon thrombin
incubation. If the cells were coincubated with APC, ATAP2 binding
was further decreased, consistent with additional cleavage of PAR1
by APC in the presence of thrombin. In contrast, coincubation with
APC led to enhanced WEDE15 binding, demonstrating that total
Figure 5. Both exogenous and endogenously generated APC support addi-
tional PAR1 cleavage in the presence of thrombin. (A) Nonfixed or PFA-fixed cells
were incubated for 3 hours with different concentrations of thrombin in the absence or
presence of APC as indicated, followed by analysis of ATAP2 binding. (B) Cells were
incubated with 20 nM thrombin for 10 minutes followed by quenching of the protease
with 50 nM hirudin. Recovery of ATAP2 binding upon incubation at 37°C over 3 hours
is plotted. Where indicated, the cells were PFA-fixed or pretreated with brefeldin A
(1 M, 10 minutes) before the addition of thrombin. A representative experiment (of 3)
is shown. (C) Brefeldin A–treated cells were incubated for 3 hours as indicated
followed by analysis of ATAP2 binding. (D) Nonfixed cells were incubated with the
indicated concentrations of thrombin in the absence or presence of 80 nM PC. After
3 hours the APC concentration in the conditioned medium was determined by
chromogenic assay and ATAP2 binding was analyzed. Means plus or minus SEM are
shown (n  9 in panels A,C,D. *P  .05, **P  .005).
Figure 6. APC cleaved PAR1 remains on the cell surface. (A) Cells were incubated
with agonists for 3 hours in the absence or presence of brefeldin A followed by
analysis of ATAP2 or WEDE15 binding by surface ELISA as indicated. Means plus or
minus SEM are shown (n  9). (B) Cells were incubated for 3.5 hours with 100 pM
hirudin without or with additional 20 nM of APC. For the final 30 minutes of incubation
either control or 500 pM of thrombin was added and cell surface–expressed PAR1
was quantified by analysis of ATAP2 and WEDE15 binding. Means plus or minus
SEM are shown (n  9, **P  .005 comparing results without and with thrombin for
final 30 minutes).
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(cleaved and uncleaved) PAR1 is increased. Because the differen-
tial between WEDE15 and ATAP2 staining corresponds to the
amount of cleaved PAR1 these findings show that treatment with
APC results in the retention of cleaved PAR1 on the cell surface in
the absence as well as in the presence of up to 1 nM thrombin.
Analysis of biotinylated cell-surface proteins by Western blotting
confirmed that coincubation with APC reproducibly led to higher
levels of PAR1 on the cell surface compared with thrombin alone
(Figure 7B). To test whether similar results are also obtained in
inflammatory cytokine-perturbed endothelial cells, we analyzed
cleavage and surface retention of PAR1 in response to incubation
with APC and thrombin in cells that were pretreated with a high
concentration of tumor necrosis factor- (TNF; Figure 7C).
TNF reduced the amount of surface-exposed native PAR1 and
PAR1 cleavage by APC was found to be slightly less efficient in
TNF-induced cells most likely because of decreased EPCR
expression. However, APC still supported significant PAR1
cleavage in both the absence and presence of thrombin and the
APC-cleaved PAR1 was surface retained, entirely consistent
with our results in quiescent cells. Although the differences
were relatively small in TNF-pretreated cells, the data show
that APC leads to a unique population of cleaved PAR1 on the
cell surface that might mediate APC’s beneficial effects in
systemic inflammation.
Discussion
In sepsis the efficient PAR1 activator thrombin is generated, and
therefore the question how any beneficial effects of APC can be
PAR1 mediated is at the root of the current controversy. So far it
was difficult to explain how APC can mediate any effects through
PAR1 because thrombin is much more efficient in cleaving this
receptor. Our data directly demonstrate for the first time that APC
can cleave endogenous PAR1 on the surface of human endothelial
cells, corroborating conclusions from studies using overexpressed
tagged PAR1 constructs16 or cleavage blocking antibodies against
PAR1.6 Exogenous and endogenously generated APC can mediate
both endothelial barrier protective signaling and additional cleav-
age of endogenous PAR1 on the endothelial cell surface even in the
presence of up to 1 nM of thrombin. The absence of detectable
additional cleavage of epitope tagged PAR1 by generated APC in a
previous study16 could be explained by preferential cleavage of the
overexpressed receptor by thrombin that binds directly to PAR1
and does not require a coreceptor.26 Our finding that APC has no
detectable additional effect on PAR1 cleavage in the presence of
high thrombin concentrations ( 1 nM) argues that any distinct
PAR1 population that can only be cleaved by APC but not by
thrombin would have to be very small. Consistent with the findings
by Bae et al26 we propose that there is a PAR1 population that is
colocalized with EPCR and that is cleaved by APC. Even though
thrombin can also cleave this PAR1 population, cleavage by APC is
efficient enough to lead to significant additional cleavage at up to
high-picomolar thrombin concentrations.
Whereas thrombin-cleaved PAR1 is rapidly internalized and
degraded,27 our data show that APC-activated PAR1 remains on the
cell surface and accumulates upon prolonged incubation even when
thrombin is present. It has been recently established that down-
stream G-protein coupling of PAR1 differs for specific agonists.31
Therefore, it is conceivable that even though thrombin and APC
activate PAR1 by cleaving the same scissile bond28 differences in
the interaction of the tethered ligand with PAR1 could lead to the
activation of distinct downstream signaling pathways and to unique
biologic responses, including distinct trafficking of thrombin- and
APC-cleaved PAR1. Such differences might also explain the
finding that thrombin and APC can have distinct effects on gene
expression through PAR1 signaling in cytokine-perturbed endothe-
lial cells.8 Our previous results demonstrate that low (40 pM) but
not high thrombin concentrations can induce endothelial barrier
protection similar to APC,11 suggesting that differences in the
PAR1 cleavage rate translate into distinct downstream signaling.
Our present results that APC can mediate protective effects in the
presence of thrombin concentrations much higher than 40 pM
indicate that differences in the cleavage rate alone cannot explain
Figure 7. APC-cleaved PAR1 is retained on the cell surface even in the presence
of thrombin. (A) Nonfixed cells were incubated for 3 hours with the indicated
agonists and cell surface–expressed PAR1 was quantified by analysis of ATAP2 and
WEDE15 binding. (B) After incubation with the indicated agonists for 3 hours, surface
proteins were biotinylated and isolated with streptavidin agarose. PAR1 was detected
by Western blotting using anti-PAR1 WEDE15. A representative experiment is shown
in the top panel. Optical density of immunoreactive bands was measured in
3 independent experiments and means plus or minus SEM are shown in the bottom
panel. Coincubation with APC led to detection of more surface PAR1 at all thrombin
concentrations, a finding that was borderline significant at lower thrombin concentra-
tions but significant at 360 pM thrombin. (C) As indicated, cells were induced with
TNF for 2 hours and thrombin and/or APC added for an additional 3 hours followed
by quantification of ATAP2 and WEDE15 binding. Means plus or minus SEM are
shown in panels A,C (n  15 in panel A and 7 in panel C, *P  .05, **P  .005,
comparing results without and with APC in panel A).
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all the findings. One possibility is that APC binding to EPCR leads
to distinct signaling of the colocalized PAR1.32 Although extensive
research will be required to elucidate molecular details of the
downstream signaling pathways and to establish that the surface-
retained PAR1 indeed mediates protective APC effects in the
presence of thrombin, our results provide conceptually novel
insight into the paradoxical condition that the 2 key coagulation
proteases thrombin and APC, linked by a negative feedback loop,
can mediate opposite effects on endothelial biology through the
same receptor PAR1.
Our finding that cellular trafficking of thrombin- and APC-
cleaved PAR1 is distinct suggests how receptor signaling by a very
inefficient protease can be relevant in the presence of the much
stronger agonist thrombin. Because of the irreversibility of proteo-
lytic activation PAR1 signaling must be regulated through mecha-
nisms such as receptor trafficking.27 Although the rate of thrombin-
PAR1 cleavage at any given point in time might be much higher
than the rate of APC-PAR1 cleavage, the thrombin-cleaved recep-
tor is rapidly internalized and degraded whereas the APC-cleaved
receptor accumulates on the surface and can potentially mediate
relevant signaling in the presence of thrombin. This illustrates how
the efficiency of induction of a specific biologic response does not
necessarily correlate with efficiency of cleavage. This concept
cannot only explain our finding that APC enhances endothelial
barrier integrity in the presence of thrombin, but it might help to
clarify the complex roles of PAR1 in vivo. PAR1 deficiency did not
affect survival in mouse models of endotoxemia,33,34 even though
PAR1 has well-established proinflammatory effects in other mod-
els, such as glomerulonephritis, inflammatory bowel disease, or
ischemia-reperfusion injury.35-37 This argues that any detrimental
effects of PAR1 deficiency in systemic inflammation might be
offset by the absence of proinflammatory PAR1 signaling. Very
recent results indeed support the conclusion that PAR1 has such
dual roles during different stages of the inflammatory response in
mouse models of severe sepsis.38,39 These findings suggest that
PAR1 mediates protective signaling by the PC pathway in vivo
under conditions where thrombin is also present. Our in vitro data
suggest that relevant protective PAR1 signaling by the PC pathway
might be possible in the presence of up to high-picomolar or
low-nanomolar thrombin. PAR1 is activated with half maximal
efficiency by a concentration of only approximately 50 pM
thrombin14 and thrombin activity in vivo is rigorously controlled to
prevent excessive platelet activation/fibrin formation. Although it
is not known what the thrombin concentration in the endothelial
cell microenvironment under conditions of inflammatory stress
might be, data from Dr Coughlin’s laboratory elegantly demon-
strate that thrombin likely operates close to threshold levels: In
murine platelets PAR4 cleavage is required for thrombin signaling
and PAR3 acts as a nonsignaling cofactor that recruits thrombin and
decreases the concentration required for half maximal signaling
between 6- and 15-fold.40 However, PAR3- and PAR4-deficient
mice showed similar degrees of protection in thrombosis models,
indicating that an approximately 10-fold decrease in platelet
responsiveness to thrombin has the same effect as complete
unresponsiveness.41,42 Based on these findings, we expect that the
range of thrombin concentrations where we obtained protective
signaling and surface retention of APC-cleaved PAR1 is of
physiologic relevance.
In conclusion, our results help explain how using a single
receptor cell can sense proteolytic activity of thrombin and APC
independently, and they support the concept that PAR1-dependent
signaling might contribute to protective effects of APC in sepsis.
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Abstract
Protease activated receptor-1 (PAR1) mediates barrier protective signaling of activated protein C
(APC) in human endothelial cells in vitro and may contribute to APC’s beneficial effects in patients
with severe sepsis. Mouse models are of key importance for translational research but species
differences may limit conclusions for the human system. We analyzed whether mouse APC can
cleave, activate and induce signaling through murine PAR1 and tested in newly established mouse
models if long term infusion of APC prevents from vascular leakage. Cell surface immunoassays
demonstrated efficient cleavage of endogenous murine endothelial PAR1 by either murine or human
APC. Pharmacological concentrations of APC of either species had powerful barrier protective
effects on cultured murine endothelial cells that required PAR1 cleavage. Vascular endothelial
growth factor-mediated hyperpermeability in the skin was reduced by either endogenously generated
as well as directly infused recombinant mouse APC in wild type mice. However APC did not
significantly alter the vascular barrier function in PAR1-deficient mice. In endotoxin challenged
mice, infused APC significantly prevented from pulmonary fluid accumulation in the wild type but
not in mice lacking PAR1. Our results directly show that murine APC cleaves and signals through
PAR1 in mouse endothelial cells. APC reduces vascular permeability in mouse models and PAR1
plays a major role in mediating these effects. Our in vitro and in vivo data support the paradigm that
PAR1 contributes to protective effects of APC on vascular barrier integrity in sepsis.
Keywords
activated protein C; endothelial cells; protease-activated receptor-1; sepsis, vascular barrier
Infusion of recombinant human activated protein C (APC) can reduce mortality in patients
with severe sepsis (1). APC downregulates the generation of thrombin, the key procoagulant
enzyme of the blood coagulation system (2,3) but these anticoagulant effects of APC are
unlikely to explain its benefit in septic patients because other anticoagulants improved the
sepsis related coagulopathy but failed to improve survival of septic patients (4,5). Consistent
with this conclusion, recent results show that a non-anticoagulant variant of APC can protect
mice in an endotoxemia model similarly well as wildtype APC (6).
APC can mediate a number of potentially protective effects in human endothelial cells that
include stabilization of barrier integrity, anti-apoptotic effects, and downregulation of adhesion
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receptors (7). These cytoprotective activities of APC require binding to the endothelial protein
C receptor (EPCR) and are at least in part mediated by signaling through the thrombin receptor
protease activated receptor-1 (PAR1), a G protein-coupled receptor that is activated by
proteolytic cleavage of its N-terminal exodomain (8,9). PAR1 has been implicated in protective
in vivo effects of APC in mouse models, including increased survival of APC treated mice in
endotoxemia (6). Both human and mouse APC has been used in mouse models but it is
unknown whether significant species differences exist in APC signaling. PAR1 is known to
play distinct roles in different species, e.g. PAR1 mediates platelet activation in humans but
not in mice (8). So far, it has never been tested directly whether human or mouse APC can
cleave and activate PAR1 on mouse endothelial cells. Indirect evidence that in the mouse APC
cleaves and activates PAR1 was drawn from in vivo studies (10) using PAR1 blocking
antibodies. However, recent reports show that APC binding to EPCR can mediate protective
PAR1-dependent signaling even if this receptor gets cleaved by another protease such as
thrombin (11). Since mouse models are widely used in translational research to understand
how APC therapy improves survival of septic patients more direct insights in whether the APC-
PAR1 pathway is conserved between mouse and humans is important.
Dysfunction of the vascular barrier is a key event in the pathogenesis of sepsis and plays an
important role in the development of organ dysfunction, such as the lung injury-triggered
development of acute respiratory distress syndrome. Previous studies have shown that APC
can attenuate acute lung injury (12,13). Enhancement of endothelial barrier integrity is a highly
sensitive downstream effect of APC-PAR1 signaling in cultured human endothelial cells that
requires crossactivation of sphingosine 1-phosphate (S1P) receptors (14,15). Given that S1P
can reduce the vascular leak in animal models of acute lung injury (16,17), it is tempting to
speculate that vascular barrier protection may contribute to beneficial effects of APC treatment
in sepsis.
Here we show that in cultured mouse endothelial cell lines APC directly cleaves and activates
endogenous PAR1 which leads to reduced permeability of an endothelial cell monolayer.
Infused or in vivo generated APC significantly enhanced vascular barrier integrity in wildtype
mice but not in PAR1-deficient mice. The findings support the concept that PAR1-dependent
protection of vascular barrier integrity contributes to beneficial effects of APC in sepsis.
METHODS
Reagents and Antibodies
Human plasma-derived APC and PAR1 agonist peptide were as described previously (9,14,
18-20). Recombinant mouse APC was made as described (21). Human WE-thrombin was
kindly provided by Dr. Di Cera (Washington University). All in vitro experiments involving
stimulation with APC included hirudin (Calbiochem, La Jolla, CA). Mouse thrombin was from
Haematologic Technologies (Essex Junction, VT). The S-19 polyclonal goat anti-mouse PAR1
(Lot# L1205) and its commercial blocking peptide (RSFFLRNPSENTFELVPLGDE) were
from Santa Cruz (Santa Cruz, CA). Additional peptides corresponding to the N-terminus of
mature mouse PAR1 were custom synthesized (CHI Scientific Inc., MA USA) and used for
mapping the PAR1 epitope recognized by the S-19 anti-PAR1 antibody. Mouse plasma IL-6
was quantified by DuoSet ELISA (R&D Systems, Minneapolis, MN) and thrombin
antithrombin complexes by the ELISA for TAT complexes (Enzyme Research Laboratories,
South Bend, IN) following the protocols of the manufactures. Mouse APC plasma levels were
determined as described (22). In brief, mouse blood was collected into vials containing 0.1 M
citrate and 10 mM benzamidine (final concentrations). After centrifugation, the plasma samples
were loaded onto wells precoated with monoclonal anti-mouse PC AMGDPC1587 (kindly
provided by Dr. Esmon; Oklahoma Health Sciences Center), incubated for 2 h, and extensively
washed with Tris buffer containing 0.05% Tween 20. Serial dilutions of recombinant mouse
Schuepbach et al. Page 2
Thromb Haemost. Author manuscript; available in PMC 2009 May 11.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
APC were used to prepare a standard curve. Amidolytic activity of pulled down proteins was
quantified by Spectrozyme PCa (#336, American Diagnostica, Stamford, CT).
Cell Culture
Transduced mouse endothelial cell lines MS1 and b.End3 were from the American Type
Culture Collection (Manassas, VA) and were grown in Dulbecco’s Modified Eagle Media
(Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (Hyclone, Logan, UT).
Results obtained with both mouse cell lines were similar throughout all in vitro assays except
for permeability assays where only the b.End3 sufficiently attached to the microporous
membrane. Plasmid transfection was performed in human EA.hy926 cells (23). Cells were
plated in tissue culture medium together with plasmids and Lipofectamine™2000 (Invitrogen,
Carlsbad, CA) which was replaced with growth medium 6 h after transfection and the cells
were used for experiments two days later. The plasmids contained the full length cDNA coding
for mouse PAR1 in the pcDNA3.1/Zeo(+) vector (Invitrogen, Carlsbad, CA). Sequence
analysis confirmed the consistency with gene bank entry #W20934. Full length human PAR4
in the same vector was used as a control.
Permeability Assay and Surface Immunoassay
The macromolecular monolayer permeability was assessed as described (14). Briefly b.End3
endothelial cells were grown to subconfluence for two days on polycarbonate membrane
transwells (Costar, 3 μM pore size) serum starved for 30 min in absence or presence of the
PAR1 blocking antibody S19. After a 3 h incubation with agonists all media were removed
and DMEM containing 0.67 mg/mL of Evans Blue and 4% bovine serum albumin was added
to the transwell compartment above the microporous membrane. Changes in endothelial
permeability were quantified by measuring the increase in absorbance at 650 nm of the medium
(DMEM containing 0.4% bovine serum albumin) placed into the bottom well. Cell surface
PAR1 was quantified by an immunoassay as described (20) except that S-19 goat anti-mouse
PAR1 at 2 μg/ml and a peroxidase-coupled rabbit anti-goat IgG (Calbiochem) were used.
Modifications of this assay were used in order to map (the) binding site(s) of S-19 on mouse
PAR1. On one hand, it was tested whether an excess (100 nM) of peptide can compete with
endogenously expressed mouse PAR1 on MS1 cells for S-19 binding. On the other hand, it
was tested whether the immobilized peptides are able to bind to S-19.
Immunoprecipitation, and Western Blotting
Cell surface proteins were biotinylated as described (20). PAR1 was immunoprecipitated with
S-19 (0.5 μg/ml) and protein G-agarose (Calbiochem). Following extensive washing, eluted
proteins were separated by SDS-PAGE, transferred to Immobilon-P-membranes (Millipore,
Bedford, MA) and biotinylated proteins were visualized with Streptavidin-HRP (Zymed, San
Francisco, CA) and the Femto detection system (Pierce). Western blotting for mitogen-
activated protein kinase phosphorylation was as reported (18). Stripped membranes were re-
probed with anti-β-actin (Sigma) and analyzed as loading controls.
Mouse Models for Vascular Barrier Integrity
All studies were approved by The Scripps Research Institute Animal Care and Use Committee
and comply with National Institutes of Health guidelines. Wildtype C57BL/6 and PAR1-
deficient mice, backcrossed for >10 generations into the C57BL/6 background, were as
described (24) and bred in-house. Jugular vein catheters were surgically implanted in age-
matched 8 to 10 week old male mice 4-7 days before experiments. Implanted mice were free
to move and without any signs of distress and systemic markers for inflammation (IL-6) and
coagulation (TAT complexes). A microprocessor controlled syringe pump infused 300 μL per
hour of vehicle (physiological saline) either alone or containing WE (200 μg/kg/h) or
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recombinant mouse APC (120 μg/kg/h). Up to 16 mice were infused simultaneously. LPS (E.
coli serotype O111:B4; Sigma, St. Louis, MO) injected mice were sacrificed at the end of the
infusion. To quantify vascular leakage in the skin, intravascular albumin was labeled with
Evans blue (1 mg in 100 μl intravenous). Recombinant murine vascular endothelial growth
factor (VEGF165; Peprotech, Rocky Hill, NJ) was intradermally injected (25 μl; 1 μg/ml) into
the preshaved abdominal skin and the injection sites were removed by dermal punch biopsies
(diameter 6 mm) 30 min later after the animal was sacrificed. The skin samples were incubated
in 200 μl of formamide at 56°C for 24 h and the extracted Evans blue content was quantified
by measuring the OD at 620 nm. Results from six samples of each animal were averaged and
used as a single data point for further data analysis. In endotoxin (LPS) challenged mice (20
mg/kg; E.coli serotype O111:B4: Sigma, St. Louis, MO) pulmonary edema was quantified by
measuring the wet to dry weight ratio of the left lung (weight obtained immediately after
extirpation divided by the weight assessed after 4 days of drying at 60°C). For histological
analysis the cardiac lung lobe was formaldehyde fixed, paraffin embedded and 10 μm
microsections stained with Hematoxylin Eosin were analyzed by light microscopy (Olympus
BX60, Olympus America INC, San Diego, CA).
Statistical Analysis
Data analysis was performed using the NCSS Statistical & Power Analysis Software. A two-
sample two-tailed homoscedastic t-test was used to compare groups of two, parametric
ANOVA was used to compare equally powered groups of more than two.
RESULTS
APC Induces Barrier Function in Mouse Endothelial Cells
In a first series of experiments we analyzed effects of APC on endothelial barrier integrity in
a dual chamber system. Mouse APC enhanced the barrier function in a dose dependent manner
in a mouse brain endothelial cell line (Fig. 1). Mouse APC was slightly more efficient than
human APC in this assay. The anti human PAR1 antibody H-111 (Santa Cruz) has been
previously reported to block cleavage and was used to establish that APC-PAR1 signaling is
required for anti apoptotic effects of APC in mouse neuronal cells (10). Unfortunately, recent
lots of this polyclonal antibody did not bind to PAR1 in cultured mouse endothelial cell lines
(data not shown), likely due to a change in the properties of this polyclonal antibody raised
against the N-terminus of human PAR1. Thus, novel tools had to be established in order to test
whether APC can directly cleave PAR1 and thereby enhance the endothelial barrier function
in mouse cells.
APC Cleaves Mouse PAR1 and the APC-cleaved Receptor is Retained on the Cell Surface
To test whether APC directly cleaves mouse PAR1 we established an immunoassay to quantify
binding of anti-PAR1 to the endothelial cell surface. Transfection studies overexpressing
mouse PAR1 in the human endothelial cell line EA.hy926 established specificity of the S-19
polyclonal goat anti-mouse PAR1 (Fig. 2A). Mouse thrombin efficiently removed anti-PAR1
epitopes from cultured mouse endothelial cells whereas mouse APC had no effect (Fig. 2B).
These results either suggest that APC cannot cleave mouse PAR1 or that APC-cleaved
receptors are not efficiently removed from the cell surface, as described recently for human
PAR1 (20). To clarify if cleavage or internalization of mouse PAR1 explains the reduced
binding of S-19 in thrombin treated cells we mapped the S-19 epitope(s) (Fig. 2C). The
commercially available S-19 blocking peptide (blocked S-19 — used throughout this study),
was sequenced and found to contain 20 amino acids beginning with R41 at the scissile bond
that leads to receptor activation. This peptide as well as the shorter, custom synthesized peptide
NE-15 (amino acids 47 to 61) competes with S-19 binding to endothelial expressed PAR1 and
support S-19 binding to the immobilized peptide. In contrast neither the peptide corresponding
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to the full length of the mouse PAR1 upstream of the scissile bond (amino acid 22 to 41) nor
any other of the custom made peptides bound to S-19 in both assays. These data show that
S-19 goat anti-mouse PAR1 antibody is not expected to be cleavage sensitive and that it
specifically binds to an epitope containing V56 and P57. Biotinylated cell surface exposed
receptors were analyzed by SDS-PAGE to assess agonist dependent cleavage. Densitometric
analysis of immunoreactive bands confirmed that the total amount of mouse PAR1 on the cell
surface is neither affected by mouse nor by human APC but significantly reduced upon
incubation with mouse thrombin (Fig. 2D), consistent with the findings from the surface
immunoassay. Importantly, both thrombin and APC led to the appearance of a smaller cleavage
product with an average apparent size of approximately 60 kDa. In order to estimate cleavage
efficiency we determined the proportion of immunoreactive products above and below PAR1’s
native average size of 82 kDa. This proportion was significantly reduced not only upon
incubation with thrombin but also after APC incubation, indicating that APC does cleave mouse
PAR1. As found previously for human PAR1 (20), APC-cleaved mouse PAR1 was surface
retained even after a short incubation with high dose thrombin (Fig. 2E) and when cells were
coincubated with thrombin and APC or zymogen protein C (not shown). Taken together, these
data show for the first time directly, that mouse PAR1 can in fact be cleaved by APC and APC-
cleaved receptors are retained on the cell surface similar as described for human PAR1.
APC Signaling and Barrier Protection in Mouse Endothelial Cells Require PAR1 Cleavage
To test the hypothesis that PAR1 cleavage is indeed necessary for APC’s effects on the barrier
function of cultured mouse endothelial cells, we screened several antibodies raised against
PAR1 for their ability to block PAR1 cleavage-mediated signaling. Only S-19 significantly
reduced thrombin- but not PAR1 agonist peptide-induced phosphorylation of Erk1/2 in mouse
endothelial cells (Fig. 3A). As expected, preincubation of S-19 with its immunizing peptide
rendered the antibody inefficient and ruled out non specific effects of S-19. Mouse APC but
not human APC induced detectable Erk1/2 phosphorylation in our assay conditions (Fig. 3B),
consistent with less efficient signaling of human APC in mouse cells. Preincubation with S-19
blocked Erk1/2 phosphorylation in response to mouse APC. Most importantly, the barrier
enhancing effect of mouse APC in cultured mouse endothelial cells was found to be blocked
in the presence of anti PAR1 S-19 (Fig. 3C), indicating that PAR1 cleavage is required for the
induction of endothelial barrier function by APC in cultured mouse endothelial cells.
Vascular Barrier Protection by APC in the Skin Requires PAR1
APC-PAR1 has powerful endothelial barrier protective effects in vitro but relatively high
concentrations of APC (>2.5 nM) were required (Fig. 1). Thus, we first attempted to test
whether APC similarly affects the vascular barrier in vivo. Based upon our in vitro studies we
expected that a prolonged exposition for several hours to APC may be necessary and that
endogenously generated APC may be more efficient compared to exogenous APC (19).
Efficient endothelial generation of APC was reported from baboons infused with mutated,
anticoagulant thrombin (WE) and WE has a much longer half life in the circulation than APC
(25,26). Human WE efficiently activated mouse protein C on cultured endothelial cells (Fig.
4A) and it was about 500 times less efficient in cleaving mouse PAR1 if compared to non
mutated mouse thrombin (Fig. 4B). Bolus injections of WE in mice resulted in efficient and
sustained in vivo generation of APC (Fig. 4C) which was comparable to reports from baboons
(26). A continuous infusion with 200 μg/kg/h of WE (without bolus) yielded plasma levels of
around 20 ng/ml, comparable to levels achieved in septic patients treated with recombinant
APC (Fig. 4D).
To directly test whether exogenous and endogenously generated APC can protect vascular
barrier integrity, we analyzed vascular endothelial growth factor (VEGF)-mediated
hyperpermeability in a skin model derived from the classic Miles assay (Fig. 5A). The dermal
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vascular bed is known to highly express EPCR as well as PAR1 and is therefore expected to
support local APC generation and APC-PAR1 signaling. Evans blue was used to label
intravascular albumin and control experiments demonstrated that the results indeed reflect
time-dependent extravasation in response to increased vascular permeability (not shown).
Infusion with WE at a dose that leads to plasma APC levels comparable to APC-treated patients
had a highly significant protective effect against VEGF-induced hyperpermeability (Fig. 5B).
Direct infusion of mouse APC at a dose (120 μg/kg/h) comparable to the one licensed for
treating septic patients also had a significant vascular barrier protective effect. To test if effects
of APC depend on PAR1 a set of wildtype and PAR1 deficient mice were parallel infused with
either saline alone or APC. Only in mice expressing PAR1 APC had significant effects (Fig.
5C). These results demonstrate that APC can enhance vascular barrier integrity in vivo and that
PAR1 plays a major role mediating this effect.
PAR1-dependent Protection from Pulmonary Edema by APC in an Endotoxemia Model
To test if APC has similar vascular barrier protective effects in systemic inflammation we
assessed pulmonary edema formation at an early time point in an endotoxemia model (Fig.
6A). Intraperitoneal injection of a lethal dose of lipopolysaccharide (LPS) led to a strong
increase of pulmonary fluid content after 5 h and APC infusion significantly reduced fluid
accumulation in wildtype animals whereas it lacked a significant protective effect in PAR1
deficient mice (Fig. 6B). Histological analysis of the lungs performed on a subset of the animals
revealed interstitial and focal alveolar edema in saline infused wild type mice as well as in both
APC treated and untreated PAR1 deficient mice whereas APC infused wild type mice showed
minimal to no alterations (Fig. 6C), consistent with the measurements of the wet to dry weight
ratio. Interleukin-6 (IL-6) plasma levels were similarly high in all groups (Fig. 6D). These
results indicate that APC leads to reduced fluid extravasation without affecting a marker of
systemic inflammation showing that PAR1 plays a central role in APC mediated enhancement
of endothelial barrier integrity in a sepsis model.
DISCUSSION
The mouse has become a unique and important tool for studying human diseases and for
screening and testing putative drugs. However, species differences limit projecting conclusions
drawn in one species onto the other. For example, thrombin signaling is mediated by PAR1 in
human platelets and by PAR3 and PAR4 in mouse platelets (8). Here we demonstrate for the
first time directly that mouse APC cleaves mouse PAR1 in endothelial cells. Using an antibody
that blocks PAR1 cleavage-mediated signaling we provide evidence that APC can directly
enhance the barrier of cultured endothelial cells by signaling through PAR1. We further show
that APC-cleaved mouse PAR1 in contrast to thrombin cleaved mouse PAR1 is cell surface
retained as described in human cell lines (20). Thus, PAR1 activation is linked to the protein
C pathway similarly in humans and mice.
Previous studies in mouse models of cerebral ischemia demonstrated protective signaling of
APC through PAR1 (10,27). Furthermore, APC treatment improved survival in an
endotoxemia model in wildtype mice but not in PAR1-deficient mice (6). In wildtype mice
APC treatment altered endotoxin-induced vascular hyperpermeability in the kidney, resulting
in decreased permeability in small vessels but increased or unchanged permeability in medium
sized or bigger vessels (6). However, this study did not analyze whether APC’s effects on
vascular permeability require PAR1. Here we extend these observations by demonstrating that
in mouse models APC infusion protects from endotoxin-mediated fluid accumulation in a
whole organ, i.e. the lung or the skin. In addition, we show for the first time that PAR1 plays
a key role mediating the vascular barrier protective properties of infused APC in vivo. Taken
together with our finding that PAR1-dependent APC signaling reduces monolayer permeability
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in cultured mouse endothelial cells, these results strongly support the concept that PAR1 plays
a major role mediating protective effects of APC on the vascular barrier integrity in vivo. How
APC-PAR1 signaling leads to reduced permeability of the vascular barrier in vivo remains to
be established. In tissue culture the endothelial barrier enhancing effect of APC requires the
activity of cellular sphingosine kinase, sphingosine 1-phosphate (S1P)-receptor-1
transactivation, and activity of the small GTPase Rac1 (14,15). Given that S1P reduces the
increased vascular permeability in animal models of acute inflammatory lung injury (28), it
seems likely that S1P pathway- and Rac1-dependent changes of the organization of the
endothelial actin cytoskeleton and cell-cell contacts also play a role in APC’s vascular barrier
protective activity in vivo.
Our results demonstrate that PAR1 plays a major role in mediating protective effects of infused
APC on pulmonary fluid accumulation in a model of endotoxemia. The inflammatory response
in this model of systemic inflammation includes strong upregulation of tissue factor expression
on monocytic cells leading to thrombin generation (29). The reported PAR1 dependent effects
could therefore either be direct by APC-PAR1 signaling or indirect by downregulation of
thrombin generation and reduced thrombin-PAR1 signaling. To avoid such strong systemic
responses we developed an animal model quantifying the dermal vascular barrier function. The
dermis was chosen because of its easy accessibility, the high expression levels of EPCR and
PAR1 within its vascular bed and its clinical relevance in protein C deficiency. VEGF acts
directly on endothelial cells and mediates a well defined hyperpermeability response in vitro
and in vivo (30). The finding that APC infusion protects vascular barrier integrity in both the
endotoxemia and the skin model in a PAR1 dependent manner while PAR1-deficiency itself
does not affect barrier integrity in either model, strongly argues that PAR1 signaling by the
infused APC is beneficial. It remains to be established whether any remaining protective effects
in the absence of PAR1 require APC’s anticoagulant activity or are mediated by novel non
PAR1-dependent APC signaling mechanisms in endothelial cells or other cell types such as
leukocytes.
Given PAR1’s role mediating vascular barrier protection by exogenously administered APC,
it seems likely that endogenously generated APC also mediates protective effects through
PAR1, especially in view of the finding that protein C activation on the endothelial surface is
coupled to highly efficient PAR1-dependent barrier protective signaling by the generated APC
in cultured endothelial cells (19). Our new data add to accumulating evidence that similar to
thrombin itself the prototypical thrombin receptor PAR1 has dual-faced physiological roles,
mediating both pro-inflammatory and protective effects. Originally PAR1 has been described
as a receptor that mediates pro-inflammatory responses (31). Even though thrombin-PAR1
signaling is indeed pro-inflammatory in mouse models of glomerulonephritis (32), renal
ischemia-reperfusion injury (33), and inflammatory bowel disease (34) PAR1 deficiency does
not affect survival in mouse models of endotoxemia (6,35,36). Thus any beneficial effects of
the absence of pro-inflammatory PAR1 signaling may be offset by the absence of
cytoprotective PAR1-dependent signaling in the endotoxemia models. In a mouse sepsis model
a pepducin PAR1 antagonist improved survival when the antagonist was administered
immediately after surgery but not when given at later time points, whereas a PAR1 agonist was
beneficial when given at late time points (37). These data indeed support the conclusion that
PAR1 has opposite roles in systemic inflammation that may depend on the stage of the
inflammatory response.
In conclusion, our results in complementary cell and mouse models demonstrate that PAR1
plays similar roles in endothelial barrier protective signaling by APC in humans and mice and
they support the concept that APC by signaling through PAR1 maintains the integrity of the
vascular barrier in systemic inflammation. The protein C pathway may have a role not only in
Schuepbach et al. Page 7
Thromb Haemost. Author manuscript; available in PMC 2009 May 11.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
containing the thrombotic response but also in preventing excessive spreading of vascular
barrier dysfunction during inflammation.
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Figure 1. Effect of APC on endothelial barrier permeability in mouse endothelial cells in tissue
culture
Subconfluent murine endothelial cells (b.End3) were incubated for 3 h with the indicated
agonists in a dual chamber system followed by analysis of permeability. Values are means
±SEM, n=6 to 10, *P<0.05.
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Figure 2. Cleavage of cell surface-exposed mouse PAR1 by APC
A) The human EA.hy926 endothelial cells were transfected with cDNA encoding mouse PAR1
(mPAR1) or control cDNA followed two days later by a 30 minutes agonist incubation. Cell
surface binding of S-19 anti-mouse PAR1 and immunizing peptide-blocked S-19 is shown. B)
Expression of PAR1 on the surface of a monolayer of murine MS1 endothelial cells was
analyzed after a 3 h incubation with the indicated agonists by cell surface ELISA using anti-
mouse PAR1 S-19. APC was used at 20 nM. C) The indicated peptides corresponding to the
N-terminal amino acid sequence of mouse PAR1 were analyzed for binding to S-19. In a
competition assay S-19 binding to cell surface expressed PAR1 was tested in the presence of
excess peptide. Direct binding of S-19 to immobilized peptides was analyzed in a peptide
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binding assay. D) Following a 3 h incubation with vehicle, 20nM of APC or 1nM of mouse
thrombin the cell surface proteins were biotinylated and PAR1 was immunoprecipitated using
S-19. Biotinylated proteins were detected on blots with peroxidase-coupled streptavidin. Bands
are shown from a representative experiment in the upper panel and density between 55 and
120 kDa was quantified in three independent repeat experiments (middle panel). The ratio of
density above and below PAR1’s native average size of 82 kDa is shown in the lower panel.
E) MS1 cells were incubated for 3 h with control or APC followed by an additional 30 min
incubation with vehicle alone or mouse thrombin (0.5 nM). Binding of S-19 anti-PAR1 was
analyzed by cell surface ELISA. Means±SEM are shown in all panels, n=3 (A), 4 (B), 3 (C,D)
and 16 (E), P values are indicated.
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Figure 3. Anti-PAR1 S-19 blocks PAR1 signaling and APC-mediated barrier protection in mouse
endothelial cells
A) ERK1/2 phosphorylation was analyzed after 7 min incubation with mouse thrombin (1 nM)
or the PAR1 agonist peptide TFLLRNPNDK (PAR1 AP; 20 μM). Where indicated anti PAR1
S-19 (25 μg/ml) alone or blocked by preincubation with excess of immunizing peptide was
added 15 min prior to the agonists. A representative blot is shown on the left side, quantitative
analyzes of S-19 immunoreactive bands are given in the right part of the figure (means±SEM)
and ANOVA reviled that S-19 only significantly affects the thrombin response (*P<0.05). B)
ERK1/2 phosphorylation in response to the indicated agonists (7 min) was analyzed in the
absence or presence of S-19. APC was used at 20 nM. Representative blot shown in the upper
part, quantification (means±SEM) of 4 independent experiments in the lower part, P value
indicated. C) Subconfluent murine endothelial cells (b.End3) were incubated for 3 h with
mouse APC (20 nM) in the absence or presence of S-19 in a dual chamber system followed by
analysis of permeability. Means±SEM, n=9; P value indicated.
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Figure 4. Human anticoagulant mutant thrombin (WE) efficiently activates mouse protein C in
vitro and in vivo but poorly activates PAR1
A) Mouse endothelial cells (MS1) were incubated for 3 h with indicated concentrations of WE
in the presence and absence of 80 nM of mouse protein C (means±SEM, n=6). B) Expression
of PAR1 on the surface of a monolayer of murine MS1 endothelial cells was analyzed after a
3 h incubation with the indicated agonists by cell surface ELISA using anti-mouse PAR1 S-19
(means±SEM, n=3). C) Plasma APC levels after a bolus injection of the indicated amounts of
WE (means±SEM, n=3) D) In two mice plasma APC levels were assessed immediately before,
during and after a 4.5 h infusion with WE.
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Figure 5. PAR1 dependent vascular barrier protection by APC in a modified Miles assay
A) Male mice were infused with saline, murine APC or WE for 4.5 h and Evans blue was
intravenously injected 30 min prior to the end of the infusion. At the end of the infusion 25 ng
of murine VEGF was intradermally injected and 30 min later the injection sites were removed
by punch biopsies. B) C57BL/6 wildtype mice were infused in parallel. Evans blue content in
VEGF-injected skin is shown. C) Evans blue content of an additional set of parallel infused
C57BL/6 wildtype and PAR1 deficient (PAR1 KO) animals. Means±SEM are shown in all
panels, n=10 per group (B, C), P values are indicated.
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Figure 6. Infusion of APC reduces pulmonary fluid accumulation in a mouse endotoxemia model
dependent on PAR1
A) Male C57BL/6 wildtype or PAR1-deficient (PAR1 KO) mice were infused with either saline
alone or with murine APC (120 μg/kg/h) for 5 h via a central venous catheter (10-12 mice per
group). LPS (20 mg/kg) was injected intraperitoneally one hour after the start of the infusion.
Lungs were dissected for wet/dry weight ratio determination at the end of the infusion period.
B) Lung wet weight/dry weight ratios are shown (means±SEM, P values indicated). Results
from non LPS injected animals are shown as a reference. C) Hematoxylin-Eosin stained
representative pulmonary tissue sections show normal alveolar tissue (arrow) alveolar edema
(gray arrow) and alveolar flooding (arrowhead). D) IL-6 plasma levels at the end of the infusion
are shown (means±SEM).
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Coagulation factor Xa cleaves protease-activated receptor-1
and mediates signaling dependent on binding to the endothelial
protein C receptor
R . A . SCHUEPBACH and M. R IEWALD
Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA, USA
To cite this article: Schuepbach RA, Riewald M. Coagulation factor Xa cleaves protease-activated receptor-1 and mediates signaling dependent on
binding to the endothelial protein C receptor. J Thromb Haemost 2010; 8: 379--88.
Summary. Background and objective: Coagulation is intrinsi-
cally tied to inﬂammation, and both proinﬂammatory and anti-
inﬂammatory responses aremodulated by coagulation protease
signaling through protease-activated receptor-1 (PAR1). Acti-
vated factor X(FXa)canelicit cellular signaling throughPAR1,
but little is known about the role of cofactors in this pathway.
Endothelial protein C receptor (EPCR) supports PAR1 signal-
ing by the protein Cpathway, and in the present studywe tested
whether EPCR mediates surface recruitment and signaling of
FXa. Methods and results: Here, we show that FXa binds to
overexpressed as well as native endothelial EPCR. PAR1
cleavage by FXa as analyzed with conformation-sensitive
antibodies and a tagged PAR1 reporter construct was strongly
enhanced ifEPCRwasavailable.Anti-EPCRfailed to aﬀect the
tissue factor-dependent activation of FX, but high concentra-
tions of FXa decreased EPCR-dependent protein C activation.
Most importantly, the FXa-mediated induction of Erk1/2
activation, expression of the transcript for connective tissue
growth factorandbarrierprotection in endothelial cells required
binding to EPCR. Conclusions: Our results demonstrate that
EPCR plays an unexpected role in supporting cell surface
recruitment, PAR1 activation, and signaling by FXa.
Keywords: endothelial cells, endothelial protein C receptor,
factor Xa, protease-activated receptor-1.
Introduction
Factor X, the zymogen clotting factor, is catalytically activated
to the active serine protease (FXa) upon binding to the cell
surface complex formed by tissue factor and protease ligand
activatedFVII (FVIIa) [1]. If theternarycomplex isnot inhibited
by tissue factor pathway inhibitor [2], FXa will dissociate,
assemble with cofactor activated clotting factor V (FVa) on cell
surfaces, and proteolytically activate prothrombin to throm-
bin, which ultimately will allow clot formation by cleaving
ﬁbrinogen and activating platelets. Thrombin in complex with
the cell surface receptor thrombomodulin also activates the
anticoagulantproteinCpathway inanegative feedback loop [3].
Beyond directly controlling coagulation, clotting factors
have non-hemostatic signaling functions that play important
roles in physiology and disease. Coagulation factors induce
signal transduction through protease-activated receptors
(PARs). These closely related G-protein-coupled receptors
allow cells to sense for proteolytic activity in their microenvi-
ronment [4]. Whereas thrombin, a major mediator of cell-
signaling events, directly binds to, cleaves and activates its
prototypical receptor PAR1, other clotting factors require
coreceptor binding. FVIIa has been shown to induce PAR2-
mediated signaling dependent on binding to tissue factor [5].
Activated protein C (APC) proteolytically activates PAR1 and
induces cytoprotective signaling in endothelial cells dependent
on binding to endothelial protein C receptor (EPCR) [6,7].
EPCR is a cell membrane glycoprotein that shares homology
with the CD1 family of major histocompatibility complex
class 1 molecules. Binding of protein C and APC to EPCR is
Ca2+-dependent and involves the c-carboxyglutamic acid
(Gla) domain of protein C [8,9].
Cellular signaling by FXa has been implicated in a variety of
conditions, including wound healing and tissue ﬁbrosis,
atherosclerosis and restenosis, airway remodeling, cancer
dissemination, and angiogenesis (see [10] for a review). In view
of these ﬁndings, therapeutic targeting of cellular signaling by
FXa seems to be a promising concept, even though many
in vitro studies have used relatively high FXa concentrations,
and a precise pathological and/or physiological role of FXa
signaling in vivo remains to be established. Accordingly, a large
number of studies have addressed the question of how cellular
FXa signaling is mediated. Previous studies have shown that
FXa can activate both PAR1 and PAR2 on a variety of
different cell types, including endothelial cells [10]. FXa in a
ternary complex with tissue factor and FVIIa can more
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efﬁciently signal through both PAR1 and PAR2 [11], but other
cofactors have also been implicated [12].
Recent studies have shown that the Gla domains of not only
APC but also of FVIIa can bind to EPCR [13--15]. Given that
FXa also contains a highly homologous Gla domain, we
hypothesized that FXa, APC and FVIIa might share one or
more coreceptors for endothelial cell surface binding, and that
EPCRmightbeoneofthem.Here,weshowthatFXadoesindeed
bind to endogenously expressed EPCR, and that cleavage of
PAR1 by FXa is strongly enhanced in the presence of EPCR.
ConsistentwithEPCR-dependentactivationofPAR1,induction
ofextracellular signal-relatedkinase (ERK)1/2phosphorylation
and expression of connective tissue growth factor (CTGF) in an
endothelial cell line were also found to depend onEPCR.
Materials and methods
Reagents
Human thrombin and PAR1 and PAR2 agonist peptides were
as previously described [6,11]. Clotting proteases blocked with
phenylanalyl-prolyl-arginyl-chloromethylketone (FPRCK; for
thrombin), dansyl-glutamyl-glycyl-arginyl-chloromethylketone
(DEGR; for APC) and biotinylated-glutamyl-glycyl-arginyl-
chloromethylketone (bEGR; for Xa and APC) were obtained
from Haematologic Technologies (Essex Junction, VT, USA),
with the exception of Gla domainless APC (Enzyme Research
Laboratories, South Bend, IN, USA). All experiments involv-
ing stimulation with FXa, APC or FVIIa included hirudin
(Calbiochem, La Jolla, CA, USA), unless indicated otherwise.
Control experiments demonstrated that hirudin alone had no
effect in any of our assays. Monoclonal anti-PAR1 ATAP2
was as previously described [16], and SPAN12/5 was recloned
from SPAN12 hybridoma cells that were kindly provided by
L. Brass [17]. Monoclonal rat anti-EPCR RCR92 (non-
blocking) and RCR252 (blocking Gla-domain binding to
EPCR) were kindly provided by K. Fukudome (Saga Medical
School, Saga, Japan) and were used at 25 lg mL)1 [18].
Amidolytic assays for APC and FXa activity were as described
previously [19]. The recombinant FXa inhibitor nematode
anticoagulant protein 5 (NAP5) was provided by G. Vlasuk
[20].
Cell culture and transfection
EA.hy926 cells [21] and primary human umbilical vein endo-
thelial cells (HUVECs; Cascade Biologics, Portland,OR,USA)
were cultivated as described previously [16,22]. In experiments
involving gene silencing, cells were plated together with
complexes of small interfering RNA (siRNA; 30 pM ﬁnal
concentration) and Lipofectamine 2000 (Invitrogen, Carlsbad,
CA, USA), according to the manufacturers instructions.
Cells were used for experiments 48 h after transfection, and the
tissue culture medium was replaced on the day before the
experiment. Chemically synthesized, double-stranded siRNA
with 19-nucleotide duplex RNA and two-nucleotide 3¢-dTdT
overhangswas obtained fromAmbion (Austin, TX,USA). The
siRNA sequences were GGGAAUAUUGCCAAUGCUAtt
(targetingPAR1),CAACCGCACUCGGUAUGAAtt (target-
ingEPCR),andGGAUCAAACUCUGCUUCCUtt(targeting
PAR4 and used as a control). Real-time polymerase chain
reaction analysis of PAR1, PAR2 and EPCR mRNA levels
was used to demonstrate the efﬁciency of downregulation of
the speciﬁc target and to rule out non-speciﬁc effects on
other genes. CHO-K1 and HEK293 cells were obtained
from the American Type Culture Collection and grown in
Dulbeccos modiﬁed Eaglesmedium (DMEM)/F12 (for CHO-
K1 cells; Invitrogen) or DMEM (for HEK293 cells; Invitro-
gen). Both media were supplemented with 10% fetal bovine
serum. The cells were transiently transfected with the
pcDNA3.1/Zeo+ plasmid vector (Invitrogen), using Lipo-
fectamine 2000. The expression constructs containing the
human PAR1 or EPCR coding sequences were as described
previously [6,11]. To obtain a PAR1 cleavage reporter con-
struct, the coding sequence of PAR1 was cloned (EcoRI/XhoI
restriction sites) into amodiﬁedpcDNA3.1/Zeo+vectorwith a
deletedApaI site.ThesignalpeptideofPAR1wasremovedusing
EcoRI and PAR1s native ApaI site, and replaced by secretory
alkaline phosphatase (SEAP). The SEAP coding sequence
containing a 5¢ EcoRI site and a frame-adjusted 3¢ ApaI site
wasakindgift fromL.Mosnier [23].HEK293cellswereused for
experiments 24 h after transfection. To obtain CHO-K1 cells
stably expressing EPCR, the pcDNA3.1/Hygro+ plasmid
containing the coding sequence for EPCR was linearized with
SapI and transfected into CHO-K1 cells. Corresponding empty
vector was used to generate control cells. Two days after
transfection, selection with hygromycin (800 lg mL)1) was
initiated. Untransfected CHO-K1 cells were found to be
eliminatedwithin5 daysifexposedto400 lg mL)1hygromycin.
After10 daysofselection,survivingcellswerecloned,andaclone
withnormalgrowthspeedandhighandstableEPCRexpression
was used for experiments.
Determination of surface binding of proteases
Cell surface protease binding was quantiﬁed using a
modiﬁed method described by Ghosh et al. [14]. Brieﬂy,
conﬂuent cell layers were washed once with Ca2+-free
Hanks buffered salt solution (HBSS) containing 5 mM
EDTA, and then with HBSS containing 1% bovine serum
albumin (BSA), 1 mM MgCl2 and 5 mM CaCl2, and kept in
this buffer for all subsequent steps. Cells were chilled and
kept on ice throughout the experiment. Following incuba-
tion with biotinylated proteases for 3 h, the cells were
washed twice, incubated for 10 min with horseradish
peroxidase (HRP)-coupled streptavidin (Invitrogen), and
washed again ﬁve times before tetramethylbenzidine was
added for spectrophotometric quantiﬁcation. Negatively
charged phospholipid-rich cell membrane domains were
quantiﬁed using biotinylated annexin V (Calbiochem)
instead of biotinylated protease in the same assay with a
15-min incubation time.
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Cell surface immunoassays, western blotting, and real-time
PCR
Cell surface PAR1 and EPCR were quantiﬁed by cell surface
enzyme-linked immunosorbent assay as described previously
[16]. PAR1 was detected with biotinylated (Mini-Biotin-XX
Protein LabelingKit; Invitrogen) mousemonoclonal SPAN12/
5 (2 lg mL)1) or ATAP2. EPCR was detected with biotiny-
lated rat monoclonal RCR252. Streptavidin-coupled HRP and
tetramethylbenzidine were used for spectrophotometric quan-
tiﬁcation of cell surface antibody binding. Immunoblotting was
performed as previously described [16]. Mitogen-activated
protein (MAP) kinase phosphorylation was detected with
rabbit anti-phospho-ERK1/2 (#9101; Cell Signaling Technol-
ogy, Beverly, MA, USA), as described previously [24]. The
optical density of immunoreactive bands was quantiﬁed using
SCION IMAGE ALPHA 4.0.3.2 software (Scion Corporation,
Frederick, MD, USA). Quantiﬁcation of mRNA encoding
EPCR or CTGF by real-time PCRwas as previously described
[25] and normalized to glyceraldehyde-3-phosphate dehydro-
genase transcript levels.
Permeability assay
Macromolecular monolayer permeability was analyzed in a
dual chamber system, using Evans blue-labeled BSA as
described previously [22,26]. Brieﬂy, EA.hy926 cells were
plated on Transwell polycarbonate membranes of 3-lm pore
size and 12-mm diameter (#3402; Corning Inc., Corning, NY,
USA). The upper and lower chambers were ﬁlled with 500 lL
and 1500 lL, respectively, of growth medium. Cells were
grown for 2 days, agonists were added in serum-free medium
containing 0.4% BSA, and permeability was assayed 3 h later,
using 0.67 mg mL)1 Evans blue diluted in growth medium
containing 4% BSA. Fresh growth medium was added to the
lower chamber, and the medium in the upper chamber was
replaced with Evans blue/BSA. After 10 min, the optical
density at 650 nm was measured in a 1 : 3 diluted 50-lL
sample from the lower chamber.
PAR1 cleavage reporter assay
HEK293 cells transiently expressing alkaline phosphatase
(AP)-tagged PAR1 were washed twice and incubated with
agonists for 20 min. The supernatants were removed, and
separated from cell debris by passing them through a cellulose
ester ﬁlter (pore size, 0.45 lm); AP activity was then quantiﬁed
using the colorimetric substrate p-nitrophenyl phosphate
(1-Step PNPP; Thermo Scientiﬁc, Rockford, IL, USA).
Statistical analysis
Data analysis was performed using NCSS STATISTICAL and
POWER ANALYSIS or SIGMASTAT 3.5 (Systat Software Inc.,
Chicago, IL, USA) software. A two-sample, two-tailed homo-
scedastic t-test was used to calculate the indicated P-values.
Results
Overexpressed EPCR supports FXa binding to the cell surface
In order to investigate whether EPCR can recruit FXa to the
cell surface, we analyzed the binding of active site-blocked
biotinylated human FXa and APC to CHO-K1 cells. Cells
were incubated at 4 C to prevent internalization of the bound
proteases. Binding to native CHO-K1 cells and mock-trans-
fected control cells was very low, indicating that CHO-K1 cells
do not signiﬁcantly express high-afﬁnity receptors for the
human proteases. Unexpectedly, CHO cells stably expressing
human EPCR (CHO-EPCR cells) bound FXa and APC with
comparable efﬁciency (Fig. 1A). Similar results were obtained
in transiently transfected HEK293 cells (not shown). Conﬂuent
monolayers of CHO-EPCR cells had expression levels of
EPCR approximately three times higher than that of native
EPCR on human endothelial EA.hy926 cells (Fig. 1B). FXa
and APC binding to CHO-EPCR cells was Ca2+-dependent
(Fig. 1C). The Gla domain-containing coagulation proteases
can bind to negatively charged phospholipids in the cell
membrane in a Ca2+-dependent manner. We therefore used
annexin V, which speciﬁcally binds to anionic phospholipids,
to test whether CHO-EPCR cells express higher levels of these
binding sites. As shown in Fig. 1D, annexin V binding was
comparable in CHO-K1, mock-transfected and CHO-EPCR
cells. Furthermore, active site-blocked biotinylated thrombin
bound similarly to control and EPCR-expressing cells
(Fig. 1E). Taken together, these data indicate that human
EPCR can support the Ca2+-dependent cell surface recruit-
ment of FXa. Active site-blocked APC, zymogen protein C,
zymogen FX and FVIIa all competed for FXa binding to
CHO-EPCR cells, consistent with the conclusion that FXa
shares binding sites withAPC andFVIIa (Fig. 1F). In contrast,
protein S, FVa and active site-blocked thrombin did not
compete with FXa--EPCR binding to CHO-EPCR cells. The
absence of competition by the Gla domain-containing pro-
tein S indicates that non-speciﬁc competition by the Gla
domain does not explain the results obtained using protein C/
APC, FX, and FVIIa.
Reduced FXa binding to the endothelial cell surface in the
presence of APC or anti-EPCR
Next, we analyzed FXa binding to human endothelial cell lines.
Binding of biotinylated FXa and APC to EA.hy926 cells was
time-dependent (not shown) and dose-dependent (Fig. 2A),
and half-maximal binding was reached for both proteases at
concentrations of approximately 30 nM. FXa binding to
primary HUVECs was comparable (Fig. 2B). Binding was
again Ca2+-dependent, because almost no surface binding was
detected in the absence of Ca2+ in the binding buffer or in the
presence of EDTA (data not shown). To determine whether the
endothelial surface binding sites for FXa are shared with other
clotting factors, we analyzed FXa binding in the presence of a
100-fold molar excess of unlabeled FX, active site-blocked
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APC, or active site-blocked thrombin. FXa binding was
signiﬁcantly reduced in the presence of FX or APC, whereas
thrombin did not compete for FXa binding (Fig. 2C). The
ﬁnding that competition by FXwas more efﬁcient than that by
APC may indicate that afﬁnities for a shared receptor on
endothelial cells are different or that one or more receptors that
support FX/Xa binding do not bind APC. To test whether
EPCR constitutes binding sites that are shared by FXa and
APC, we used the RCR-252 monoclonal anti-EPCR, which is
known to block the interaction of APC with EPCR. RCR-252
did indeed reduce surface binding of both APC and FXa to
similar degrees (Fig. 2D), suggesting that EPCR is a major
binding receptor for FXa on the EA.hy926 cell surface.
Gla-domain-dependent cleavage of endothelial PAR1 by FXa
Cell surface immunoassays were used to quantify cleavage of
endogenous endothelial PAR1 by FXa. We have previously
established that ATAP2 is conformation-sensitive and does not
bind to cleaved PAR1 in the immunoassay [16]. SPAN12/5
anti-PAR1 was raised against a peptide spanning the cleavage
site, and is expected to be cleavage-sensitive [17]. Small
interfering RNA targeting PAR1 reduced PAR1 message
and antigen to< 5% (data not shown). Cell surface binding of
SPAN12/5 was reduced close to baseline if cells were pretreated
with siRNA targeting PAR1 or if the SPAN12/5 epitope on
PAR1s N-terminus was removed by the speciﬁc agonist
thrombin, demonstrating that SPAN12/5 speciﬁcally binds to
full-length uncleaved PAR1 (Fig. 3A). A 3-h incubation with
both FXa and APC signiﬁcantly reduced binding of monoclo-
nal anti-PAR1 ATAP2 and SPAN12/5 (Fig. 3B). As expected,
FVIIa had no effect on anti-PAR1 binding. The downregula-
tion of SPAN12 staining after a 30-min incubationwith FXa as
well as APCwas dose-dependent, with highly signiﬁcant effects
already being seen at a protease concentration of 12.5 nM. The
Gla-domain-deﬁcient corresponding proteases had amidolytic
activity similar to the that of the wild type (data not shown),
but did not downregulate SPAN12/5 staining at up to 50 nM
(Fig. 3C). The FXa inhibitor NAP5 blocked FXa but not APC
responses, demonstrating speciﬁcity and the dependence on
FXas proteolytic activity (Fig. 3D). These results directly
demonstrate, for the ﬁrst time, that FXa leads to cleavage of
native endothelial PAR1 dependent on its Gla domain and
proteolytic activity.
EPCR supports PAR1 cleavage by FXa
After having established an assay that allows the speciﬁc and
sensitive quantiﬁcation of PAR1 cleavage by FXa, and in view
of our evidence for substantial binding of FXa to EPCR, we
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tested whether FXa requires EPCR coreceptor binding in order
to efﬁciently cleave PAR1. We ﬁrst investigated whether
monoclonal anti-EPCR prevents PAR1 cleavage. Both FXa
and APC were found to efﬁciently cleave PAR1 in the absence
of anti-EPCR and in the presence of the non-blocking anti-
EPCR RCR92. In contrast, the blocking anti-EPCR RCR252
completely prevented the downregulation of SPAN12/5 bind-
ing by FXa and APC (Fig. 4A). Cleavage of PAR1 low-dose
thrombin was not affected by anti-EPCR. Two different
complementary approaches were used to independently con-
ﬁrm the surprising ﬁnding that EPCR is required for PAR1
cleavage by FXa in endothelial cells. First, we used siRNA to
downregulate EPCR expression in EA.hy926 cells. Transcript
levels for EPCR in the transfected cells were below 20% of
those in control transfected cells under our experimental
conditions, and surface protein expressionwas reduced by 60%
(Fig. 4B). This moderate downregulation was associated with a
highly signiﬁcant decrease in the efﬁciency of PAR1 cleavage
by FXa andAPC, whereas the effects of thrombin and plasmin
on SPAN12/5 binding were unchanged (Fig. 4C). Importantly,
downregulation of EPCR did not affect native PAR1 expres-
sion. Second, we used a reporter construct that encodes AP
fused to the N-terminus of human PAR1 to directly analyze
PAR1 cleavage in HEK293 cells. Coexpression of EPCR led to
signiﬁcantly more efﬁcient release of AP by FXa and APC
from the reporter construct (Fig. 5A). This ﬁnding was not
caused by increased surface expression of AP-tagged PAR1 in
the EPCR-cotransfected cells, as shown in Fig. 5B. AP release
by both proteases was dose-dependent, with signiﬁcant effects
being seen already at 12.5 nM (Fig. 5C). FXa and, to a lesser
extent, APC also led to AP release in cells only transfected with
PAR1, but both proteases were signiﬁcantly more efﬁcient if
EPCR was also expressed. Thus, EPCR supports FXa-
mediated cleavage of both endogenous endothelial PAR1
and overexpressed tagged PAR1 in the HEK293 cell system.
EPCR coreceptor binding does not affect FX activation
The endothelial cell surface is highly organized and compart-
mentalized, and we tested whether the interaction with EPCR
might play a role in modulating activation of FX by the tissue
factor--FVIIa complex. Quiescent EA.hy926 cells express only
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minimal amounts of tissue factor, and were found to margin-
ally support FXa generation, whereas tumor necrosis factor-a
(TNF-a)-induced cells supported substantial FXa generation.
Blocking of EPCR had no effect on FXa generation in
quiescent or TNF-a-stimulated cells (Fig. 6A). EPCR binding
of protein C increases activation efﬁciency by the thrombin--
thrombomodulin complex, and it was recently reported that
high concentrations of FVIIa can decrease protein C activation
slightly by competing for EPCR binding [14]. We found that
high concentrations of FXa, FVIIa (Fig. 6B) or APC--DEGR
(not shown) do, indeed, all similarly interfere with APC
generation, providing additional evidence that APC, FVIIa
and FXa all compete for EPCR binding on the endothelial
surface.
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EPCR binding is required for downstream signaling by FXa
We analyzed whether EPCR coreceptor binding is also
required for downstream signaling responses to FXa in
endothelial cells. Endothelial cells express both PAR1 and
PAR2, and FXa has been shown to elicit signaling through
both of these PARs. FXa and APC, as well as the PAR1-
speciﬁc and PAR2-speciﬁc agonist peptides, substantially
induced phosphorylation of ERK1/2MAPkinase in EA.hy926
cells. If the cells were preincubated with EPCR-blocking
antibodies, phospho-MAP kinase induction by FXa and APC
was abolished, whereas responses to the agonist peptides were
not affected, demonstrating that both PAR1 and PAR2 were
still available for signal transduction (Fig. 7A). FXa signaling
has been shown to induce a proﬁbrotic response, including the
induction of CTGF [27]. Induction of the CTGF transcript by
FXa was strongly reduced in the presence of blocking anti-
0.7A
B
0.6
0.5
0.3
Xa
 g
en
er
a
te
d 
[nM
]
AP
C 
ge
ne
ra
te
d 
[n M
]
0.4
0.2
0.1
10
8
6
4
2
0
0 80
Xa-bEGR [nM] VIIa [nM]
800 0 80 800
0
No antibody ControlantibodyRCR252
*
**
**
*
Control TNF
Fig. 6. Effect of FXa--endothelial protein C receptor (EPCR) interaction
on FXa and activated protein C (APC) generation. (A) EA.hy926 cells
were serum-starved for 5 h in the absence or presence of 1 nM tumor
necrosis factor-a (TNF-a) and incubated with FVIIa (20 nM) and FX
(100 nM) in the absence or presence of RCR252 or an isotype-matched
non-speciﬁc control antibody (25 lg mL)1). The generated FXa was
quantiﬁed by amidolytic assay. (B) Cells were incubated with protein C
(80 nM) and thrombin (1 nM) for 1 h in the presence of the indicated
concentrations of competitors for EPCRbinding, and this was followed by
quantiﬁcation of the generated APC. Data are given as mean ± standard
error of the mean. n = 3, *P < 0.05 and **P < 0.005 as compared with
no competitor. bEGR.
Control
Xa
50 n
M
PAR
2 AP
PAR
1 AP
APC
20 n
M
Control
RCR252
Control
RCR252
*
RCR252
pERK1/2
β-Actin
60
*
*
*
50
40
30
20
10
Pe
rm
e
a
bi
lity
 [O
D6
50
]
D
en
si
ty
 [a
rbi
tra
ry
 u
ni
ts
]
0
– + +– +– +–+–
Agonist
5
4
3
2
1
0
CT
G
F 
ex
pr
es
sio
n
[fo
ld
 in
du
ct
io
n]
Control
0.3
0.2
0.1
0
Xa 50 nM PAR2 AP
Control Xa 50 nM PAR2 AP
A
B
C
Fig. 7. Effect of blocking endothelial protein C receptor (EPCR)
binding on downstream signaling by FXa in endothelial cells.
(A) EA.hy926 cells were serum-starved in the absence or presence of
a non-specific isotype-matched rat antibody or anti-EPCR RCR252
(both at 25 lg mL)1), and this was followed by a 7-min incubation
with the indicated proteases and agonist peptides [alkaline phosphatase
(AP); protease-activated receptor-1 (PAR1) AP was TFLLRNPNDK
at 20 lM; protease-activated receptor-2 (PAR2) AP was SLIGRL at
25 lM]. The upper part of the panel shows a representative immunoblot,
and the lower part shows quantitative analyses of another set of four
experiments. b-Actin was used as a loading control to normalize the
quantitative results. (B) Connective tissue growth factor (CTGF) tran-
script expression was analyzed by real-time polymerase chain reaction
after a 3-h incubation of EA.hy926 cells with the indicated agonists.
Results were normalized to glyceraldehyde-3-phosphate dehydrogenase
transcript levels. (C) Subconﬂuent cells in a Transwell chamber were
incubated for 3 h with the indicated agonists, and permeability was
determined as described in Materials and methods. Data are given as
means ± standard errors of the mean. n = 4. *P < 0.05. APC,
activated protein C; pERK, phosphorylated extracellular signal-related
kinase.
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EPCR (Fig. 7B). We have previously shown that FXa can
mediate endothelial barrier protective signaling through either
PAR1 or PAR2 signaling [26]. Blocking anti-EPCR signiﬁ-
cantly reduced barrier enhancement by FXa in a dual chamber
assay (Fig. 7C). Thus, downstream signaling by FXa requires
binding to EPCR in our assays.
Discussion
Using several approaches, that is, overexpression of EPCR in
different cell lines, EPCR-blocking antibodies, and reducing
endothelial cell surface expression of EPCR, we have demon-
strated that EPCR supports surface binding, PAR1 cleavage,
and signaling by FXa. EPCR was recently shown to also bind
FVIIa [13--15], and our results add to accumulating evidence
that this receptor is able to support cell recruitment and
positioning of Gla-domain-containing proteins other than
protein C. Previous studies analyzing binding of APC to the
endothelial cell surface indicated that FX and FXa compete
only very inefﬁciently for binding [28]. In contrast, recent
results from Ghosh et al. [14] indicate that on the endothelial
cell surface, FX and protein C are similarly efﬁcient in
competing for EPCR binding of FVIIa, and cocompetition
of protein C plus FX did not additionally affect FVIIa binding,
suggesting that APC, FVIIa and FX share binding sites.
Interestingly, however, FX failed to compete for FVIIa binding
to EPCR-transfected CHO-K1 cells in the study by Ghosh
et al., whereas FX efﬁciently competed for FXa binding in our
studies in stably transfected CHO-K1 cells (Fig. 1F). The Gla
domains of both human protein C and FVII contain a leucine
at position 8, and this residue has been shown to be crucial for
EPCR recognition using puriﬁed proteins in surface plasmon
resonance studies [13]. Given that human FX contains a
methionine at this position, it is possible that EPCR is
necessary but not sufﬁcient for FXa binding, and that cell
type-speciﬁc differences in the expression of other cofactor(s)
that contribute to EPCR-dependent and EPCR-independent
binding may explain the conﬂicting results in competition
studies. One other such cofactor may be annexin 2, which was
recently implicated as an endothelial cell receptor that supports
PAR1-dependent signaling by FXa [12]. Another possibility is
that different forms of EPCR itself have speciﬁc relative
afﬁnities for the various ligands. Extensive studies in puriﬁed
systems, using EPCR from different sources, will be required to
quantitatively establish binding afﬁnities and competition
efﬁciencies of the coagulation proteases for EPCR binding.
Analysis of these data, together with results obtained using cell
surface-expressed EPCR, may reconcile the discrepant results
in the literature.
EPCR supports PAR1 activation by APC [6], and is
known to colocalize with PAR1 in lipid rafts in the cell
membrane [29]. Consistent with the concept that EPCR can
recruit and position coagulation proteases in close proximity
to PAR1 for efﬁcient activation, our results directly demon-
strate that cleavage of endothelial PAR1 by FXa depends to
a large extent on the availability of EPCR binding. However,
endothelial cells express high levels of both PAR1 and
PAR2, and one fundamental difference between APC and
FXa is that APC signaling seems to be completely PAR1-
dependent, whereas FXa can activate both PAR1 and PAR2
on endothelial cells. Speciﬁcally, we have previously shown
that FXa can mediate the induction of MAP kinase
phosphorylation and barrier protection in EA.hy926 cells
through either PAR1 or PAR2 [26]. Our present ﬁnding that
both of these downstream responses to FXa in the same cell
system depend on EPCR thus indicates that PAR2 activation
by FXa also requires EPCR binding and suggests that EPCR
also colocalizes with PAR2 in the cell surface. If this turns
out to be the case, another question will be why endothelial
PAR2 supports FXa signaling but not APC signaling, given
that APC can activate PAR2 in an overexpression system [6].
One possibility is that post-translational modiﬁcations, for
example glycosylation [30] of PAR2, play a role in restricting
activation to certain proteases in endothelial cells. Clearly,
further studies and novel tools will be required to directly
analyze cleavage of endogenous PAR2 in endothelial cells in
order to address these questions.
The physiological or pathophysiological role of FXa signal-
ing remains to be established, even though a variety of cellular
responses of potential relevance have been described in cell
culture [10]. Our current study shows that EPCR binding plays
an important role in PAR activation by FXa and both FXas
proﬁbrotic effects (CTGF induction) and the potentially
cytoprotective and anti-inﬂammatory barrier enhancement. It
is possible that other cellular responses to FXa are EPCR-
independent. However, PAR activation has been implicated in
most FXa responses in cells, and it is therefore likely that
expanding the scope of the present studies will lead to the
discovery of other downstream effects of FXa that are EPCR-
dependent. Relatively high FXa concentrations of unknown
physiological relevance were used in most in vitro studies.
However, these concentrations may be reached locally, result-
ing in FXa-dependent signaling, for example in the microen-
vironment of endothelial and tumor cells [31]. Many cancer cell
lines are known to express not only PARs but also EPCR [32].
EPCR binding may not only play a key role in FXa signaling,
butmay also create a pool of FX/Xa on the cellular surface and
affect the clearance and trafﬁcking of this coagulation factor
across cell barriers [33]. In conclusion, our results demonstrate
that EPCR plays a key role in supporting cell surface
recruitment, PAR1 cleavage and signaling by FXa in endo-
thelial cells. Thus, EPCR constitutes an unexpected link where
the protein C and FX pathways intersect. Further studies are
needed to address the implications of this crosstalk for potential
approaches to the therapeutic targeting of proinﬂammatory
and anti-inﬂammatory cellular signaling by FXa and APC.
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